Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience.

Autor:	Kalariya NM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Hildebrandt MAT; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Hansen DK; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Sidana S; Stanford University School of Medicine, Stanford, CA., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Ferreri CJ; Atrium Health, Wake Forest University School of Medicine, Levine Cancer Institute, Charlotte, NC., Doyle WN; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Castaneda-Puglianini O; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Freeman CL; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Hovanky V; Stanford University School of Medicine, Stanford, CA., Hosoya H; Stanford University School of Medicine, Stanford, CA., Shune LO; The University of Kansas Medical Center, Kansas City, KS., Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2024 Sep 10; Vol. 8 (17), pp. 4679-4688.
DOI:	10.1182/bloodadvances.2024013540
Abstrakt:	Abstract: The safety and efficacy of chimeric antigen receptor T-cell therapy is not well described in older patients, a population that has higher frailty and comorbidities. In this multicenter retrospective study, we evaluated clinical outcomes along with frailty and geriatric characteristics such as comorbidities, polypharmacy, falls, neuropathy, organ dysfunction, and performance status in younger (aged <65 years) vs older (aged ≥65 years) patients who received commercial idecabtagene vicleucel (ide-cel). A total of 156 patients (n = 75, aged ≥65 years) were infused with ide-cel by data cutoff. In older patients (median age: 69 years; range, 65-83; 66.7% frail; 77.3% did not meet KarMMa eligibility criteria), with a median follow-up duration of 14.2 months, best overall response rate (ORR) was 86.7%, which was comparable with pivotal KarMMa study results (ORR: 73%). Median progression-free survival and overall survival in older patients were 9.1 months and 26.5 months, respectively. Grade ≥3 cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome were observed in 1% and 4% of older patients, respectively. Compared with younger patients, the older patients had significantly higher prevalence of frailty, geriatric characteristics such as polypharmacy (≥5 drugs; 97%), ≥4 comorbidities (69%), and organ dysfunction (35%; P < .05). The safety and efficacy of ide-cel therapy were similar in younger and older patients. Frailty and geriatric characteristics such as polypharmacy, comorbidities, and organ dysfunction in older patients did not confer an inferior overall outcome. (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu